Terms: = Leukemia AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9
1254 results:
1. The Role of Diet in the Cardiovascular Health of Childhood Cancer Survivors-A Systematic Review.
Li R; Barker AR; Vlachopoulos D; Paris D; Schindera C; Belle FN; Revuelta Iniesta R
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732563
[TBL] [Abstract] [Full Text] [Related]
2. Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report.
Nagamatsu Y; Isoda T; Inaji M; Oyama J; Niizato D; Tomomasa D; Mitsuiki N; Yamashita M; Kamiya T; Imai K; Kanegane H; Morio T; Takagi M
BMC Pediatr; 2024 May; 24(1):304. PubMed ID: 38704558
[TBL] [Abstract] [Full Text] [Related]
3. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Iyer S; Ferrajoli A; Danilov AV; Giordano SH
JCO Clin Cancer Inform; 2024 Apr; 8():e2300223. PubMed ID: 38684043
[TBL] [Abstract] [Full Text] [Related]
5. A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS).
Ballantyne E; Evans C; Shepherd L; Fulbright H; Wakeling S; Phillips B; Morgan JE
Pediatr Blood Cancer; 2024 Jun; 71(6):e30952. PubMed ID: 38566349
[TBL] [Abstract] [Full Text] [Related]
6. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract] [Full Text] [Related]
7. Design of Experimental Approach for Development of Rapid High Performance Liquid Chromatographic Process for Simultaneous Estimation of metoprolol, Telmisartan, and Amlodipine from Formulation: Greenness and Whiteness Evaluation.
Attimarad M; Alali MJ; Alali HA; Alabdulmuhsin DH; Alnajdi AK; Venugopala KN; Nair AB
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474605
[TBL] [Abstract] [Full Text] [Related]
8. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
Yadav AK; Wang S; Shin YM; Jang BC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
[TBL] [Abstract] [Full Text] [Related]
9. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via met/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
10. [Venetoclax Combined with CACAG Regimen in the Treatment of Patients with Refractory/Relapse Acute Myeloid leukemia: A Prospective Clinical Study].
Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
[TBL] [Abstract] [Full Text] [Related]
11. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic leukemia and Lymphoma during maintenance therapy.
Barone T; Dandekar S; McKeone D; Mulieri K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
[TBL] [Abstract] [Full Text] [Related]
12. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
[TBL] [Abstract] [Full Text] [Related]
13. meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
Li L; Zhao Z; Li X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
[TBL] [Abstract] [Full Text] [Related]
14. Patient and caregiver perceptions of the possibility of home blood transfusions.
Binder AF; Hossain A; Doshi R; Vivero A; Gonzalez KM; Gentsch A; Wilde L; Rising KL
Transfusion; 2024 Mar; 64(3):483-492. PubMed ID: 38263774
[TBL] [Abstract] [Full Text] [Related]
15. Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review.
Bhasin S; Brown J; Dorste A; Samsel C; Vrooman LM; Muriel AC
Pediatr Blood Cancer; 2024 Apr; 71(4):e30881. PubMed ID: 38263506
[TBL] [Abstract] [Full Text] [Related]
16. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC leukemia PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract] [Full Text] [Related]
17. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
18. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic leukemia (CLL).
Chirino A; Montoya S; Safronenka A; Taylor J
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137005
[TBL] [Abstract] [Full Text] [Related]
19. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
[TBL] [Abstract] [Full Text] [Related]
20. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; Smith SD; Dorritie K; Jia T; Pham S; Huw LY; Jing J; Wu H; Ead WS; To I; Batlevi CL; Wei MC; Chavez JC
Nat Med; 2024 Jan; 30(1):229-239. PubMed ID: 38072960
[TBL] [Abstract] [Full Text] [Related]
[Next]
